{"brief_title": "Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen", "brief_summary": "This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.", "condition": ["Human Immunodeficiency Virus"], "intervention_type": ["Drug"], "intervention_name": ["Capravirine"], "criteria": "Inclusion Criteria: - Male or female at least 18 years old - HIV RNA level >1000 copies/mL at screening - CD4 >50 cells/uL at screening - Patient is currently taking a regimen that includes an NNRTI plus 2 NRTIs for at least 28 days and is currently failing this regimen - Patient has adequate hematology tests (absolute neutrophil count >1000/uL, Platelets>75,000uL, hemoglobin 9g/L) - Patient has adequate renal function (serum creatinine of <1.5 upper limit of normal) - Patient has adequate liver function (AST, ALT, and bilirubin < 2.5 upper limit of normal) Exclusion Criteria: - Previous use of protease inhibitors (except if patient has short duration of PI and was switched for tolerability reasons when viral load was <50 copies) This exception does not include Viracept - Women who are pregnant or lactating", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "HIV Infections", "mesh_term": ["Immunologic Deficiency Syndromes", "Acquired Immunodeficiency Syndrome", "HIV Infections", "Reverse Transcriptase Inhibitors", "Nelfinavir"], "id": "NCT00051844"}